Skip to main content Accessibility help
×
Home

Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning

  • Teresa Sánchez-Gutiérrez (a1), Belén Fernandez-Castilla (a2), Sara Barbeito (a1), Ana González-Pinto (a3), Juan Antonio Becerra-García (a1) and Ana Calvo (a1)...

Abstract

Background.

The implications of cannabis use in the onset of early psychosis and the severity of psychotic symptoms have resulted in a proliferation of studies on this issue. However, few have examined the effects of cannabis use on the cognitive symptoms of psychosis (i.e., neurocognitive functioning) in patients with first-episode psychosis (FEP). This systematic review and meta-analysis aim to assess the neurocognitive functioning of cannabis users (CU) and nonusers (NU) with FEP.

Methods.

Of the 110 studies identified through the systematic review of 6 databases, 7 met the inclusion criteria, resulting in 14 independent samples and 78 effect sizes. The total sample included 304 CU with FEP and 369 NU with FEP. The moderator variables were age at first use, duration of use, percentage of males, and age.

Results.

Effect sizes were not significantly different from zero in any neurocognitive domain when users and NU were compared. Part of the variability in effect sizes was explained by the inclusion of the following moderator variables: (1) frequency of cannabis use (β = 0.013, F = 7.56, p = 0.017); (2) first-generation antipsychotics (β = 0.019, F = 34.46, p ≤ 0.001); and (3) country where the study was carried out (β = 0.266, t = 2.06, p = 0.043).

Conclusions.

This meta-analysis indicates that cannabis use is not generally associated with neurocognitive functioning in patients with FEP. However, it highlights the deleterious effect of low doses of cannabis in some patients. It also stresses the importance of the type of antipsychotic prescription and cannabis dose as moderator variables in the neurocognitive functioning of CU with FEP.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning
      Available formats
      ×

Copyright

This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author

Teresa Sánchez-Gutiérrez, E-mail: teresa.sanchez@unir.net

References

Hide All
[1]Room, R, Fisher, B, Hall, W, Lenton, S, Reuter, P. Cannabis policy: moving beyond stalemate; 2010.
[2]Marconi, A, Di Forti, M, Lewis, CM, Murray, RM, Vassos, E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42:12621269.
[3]Červený, J, Chomynová, P, Mravčík, V, van Ours, JC. Cannabis decriminalization and the age of onset of cannabis use. Int J Drug Policy. 2017;43:122129.
[4]Chouvy, PA, Macfarlane, J. Agricultural innovations in Morocco's cannabis industry. Int J Drug Policy. 2018;58:8591.
[5]Englund, A, Freeman, TP, Murray, RM, McGuire, P. Can we make cannabis safer? Lancet Psychiatry. 2017;4:643648.
[6]Raber, JC, Elzinga, S, Kaplan, C. Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J Toxicol Sci. 2015;40:797803.
[7]Di Forti, M, Marconi, A, Carra, E, Fraietta, S, Trotta, A, Bonomo, M, et al.Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2:233238.
[8]Hiemstra, M, Nelemans, SA, Branje, S, van Eijk, KR, Hottenga, JJ, Vinkers, CH, et al.Genetic vulnerability to schizophrenia is associated with cannabis use patterns during adolescence. Drug Alcohol Depend. 2018;190:143150.
[9]van Os, J, Bak, M, Hanssen, M, Bijl, RV, de Graaf, R, Verdoux, H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156:319327.
[10]van Os, J, Hanssen, M, de Graaf, R, Vollebergh, W. Does the urban environment independently increase the risk for both negative and positive features of psychosis? Soc Psychiatry Psychiatr Epidemiol. 2002;37:460464.
[11]Bioque, M, García-Bueno, B, Macdowell, KS, Meseguer, A, Saiz, PA, Parellada, M, et al.Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology. 2013;38:25682577.
[12]Rubino, T, Zamberletti, E, Parolaro, D. Adolescent exposure to cannabis as a risk factor for psychiatric disorders. J Psychopharmacol. 2012;26:177188.
[13]Zamberletti, E, Rubino, T, Parolaro, D. The endocannabinoid system and schizophrenia: integration of evidence. Curr Pharm Des. 2012;18:49804990.
[14]Matheson, SL, Shepherd, AM, Laurens, KR, Carr, VJ. A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia. Schizophr Res. 2011;133:133142.
[15]Hall, W, Degenhardt, L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374:13831391.
[16]Bagot, KS, Milin, R, Kaminer, Y. Adolescent initiation of cannabis use and early-onset psychosis. Subst Abus. 2015;36:524533.
[17]Henquet, C, Krabbendam, L, Spauwen, J, Kaplan, C, Lieb, R, Wittchen, HU, et al.Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005;330:11.
[18]Foti, DJ, Kotov, R, Guey, LT, Bromet, EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 2010;167:987993.
[19]Moore, TH, Zammit, S, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M, et al.Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319328.
[20]Henquet, C, Murray, R, Linszen, D, van Os, J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005;31:608612.
[21]Semple, DM, McIntosh, AM, Lawrie, SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005;19:187194.
[22]Scott, JC, Slomiak, ST, Jones, JD, Rosen, AFG, Moore, TM, Gur, RC. Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. JAMA Psychiatry. 2018;75:585595.
[23]Bioque, M, Cabrera, B, García-Bueno, B, Mac-Dowell, KS, Torrent, C, Saiz, PA, et al.Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis. J Psychiatr Res. 2016;75:1421.
[24]Dean, B, Sundram, S, Bradbury, R, Scarr, E, Copolov, D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience. 2001;103:915.
[25]Leweke, FM, Giuffrida, A, Wurster, U, Emrich, HM, Piomelli, D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10:16651669.
[26]Muguruza, C, Lehtonen, M, Aaltonen, N, Morentin, B, Meana, JJ, Callado, LF. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophr Res. 2013;148:145150.
[27]Di Forti, M, Sallis, H, Allegri, F, Trotta, A, Ferraro, L, Stilo, SA, et al.Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40:15091517.
[28]Schoeler, T, Petros, N, Di Forti, M, Klamerus, E, Foglia, E, Ajnakina, O, et al.Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry. 2016;3:947953.
[29]Gonzalez-Pinto, A, Vega, P, Ibanez, B, Mosquera, F, Barbeito, S, Gutierrez, M, et al.Impact of cannabis and other drugs on age at onset of psychosis. J Clin Psychiatry. 2008;69:12101216.
[30]Donoghue, K, Doody, GA, Murray, RM, Jones, PB, Morgan, C, Dazzan, P, et al.Cannabis use, gender and age of onset of schizophrenia: data from the ÆSOP study. Psychiatry Res. 2014;215:528532.
[31]Tosato, S, Lasalvia, A, Bonetto, C, Mazzoncini, R, Cristofalo, D, De Santi, K, et al.The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). J Psychiatr Res. 2013;47:438444.
[32]Bogaty, SER, Lee, RSC, Hickie, IB, Hermens, DF. Meta-analysis of neurocognition in young psychosis patients with current cannabis use. J Psychiatric Res. 2018;99:2232.
[33]Mata, I, Rodríguez-Sánchez, JM, Pelayo-Terán, JM, Pérez-Iglesias, R, González-Blanch, C, Ramírez-Bonilla, M, et al.Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. Psychol Med. 2008;38:12571266.
[34]Gonzalez-Pinto, A, Gonzalez-Ortega, I, Alberich, S, Ruiz de Azua, S, Bernardo, M, Bioque, M, et al.Opposite cannabis-cognition associations in psychotic patients depending on family history. PLoS ONE. 2016;11:e0160949.
[35]Yucel, M, Bora, E, Lubman, DI, Solowij, N, Brewer, WJ, Cotton, SM, et al.The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull. 2012;38:316330.
[36]Cunha, PJ, Rosa, PG, AeM, A, Duran, FL, Santos, LC, Scazufca, M, et al.Cannabis use, cognition and brain structure in first-episode psychosis. Schizophr Res. 2013;147:209215.
[37]Leeson, VC, Harrison, I, Ron, MA, Barnes, TR, Joyce, EM. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr Bull. 2012;38:873880.
[38]Yücel M, BE, Lubman, DI, Solowij, N, Brewer, WJ, Cotton, SM, Conus, P, et al.The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull. 2012;38:316330.
[39]Rodríguez-Sánchez, JM, Ayesa-Arriola, R, Mata, I, Moreno-Calle, T, Perez-Iglesias, R, González-Blanch, C, et al.Cannabis use and cognitive functioning in first-episode schizophrenia patients. Schizophr Res. 2010;124:142151.
[40]Bugra, H, Studerus, E, Rapp, C, Tamagni, C, Aston, J, Borgwardt, S, et al.Cannabis use and cognitive functions in at-risk mental state and first episode psychosis. Psychopharmacology. 2013;230:299308.
[41]Moher, D, Shamseer, L, Clarke, M, Ghersi, D, Liberati, A, Petticrew, M, et al.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
[42]de la Serna, E, Mayoral, M, Baeza, I, Arango, C, Andrés, P, Bombin, I, et al.Cognitive functioning in children and adolescents in their first episode of psychosis: differences between previous cannabis users and nonusers. J Nerv Ment Dis. 2010;198:159162.
[43]Harrell, PT, Mancha, BE, Martins, SS, Mauro, PM, Kuo, JH, Scherer, M, et al.Cognitive performance profiles by latent classes of drug use. Am J Addict. 2014;23:431439.
[44]Thoma, RJ, Monnig, MA, Lysne, PA, Ruhl, DA, Pommy, JA, Bogenschutz, M, et al.Adolescent substance abuse: the effects of alcohol and marijuana on neuropsychological performance. Alcohol Clin Exp Res. 2011;35:3946.
[45]Hedges, LV. Distribution theory for Glass’s estimator of effect size and related estimators. J Educ Stat. 1981;6:107128.
[46]Becker, JBMultivariate meta-analysis. In: HEA, Tinsley, Brown, ED, editors. Handbook of applied multivariate statistics and mathematical. Orlando FL: Academic Press; 2000. p. 499525.
[47]Van den Noortgate, W, López-López, JA, Marín-Martínez, F, Sánchez-Meca, J. Three-level meta-analysis of dependent effect sizes. Behav Res Methods. 2013;45:576594.
[48]Van den Noortgate, W, López-López, JA, Marín-Martínez, F, Sánchez-Meca, J. Meta-analysis of multiple outcomes: a multilevel approach. Behav Res Methods. 2015;47:12741294.
[49]Wibbelink, CJM, Assink, M. Manual for conducting a three-level meta-analysis in R. Amsterdam, Netherlands: Universiteit van Amsterdam, 2015.
[50]Cheung, MW. Modeling dependent effect sizes with three-level meta-analyses: a structural equation modeling approach. Psychol Methods. 2014;19:211229.
[51]Rosenthal, R. The file drawer problem and tolerance for null results. Psychol Bull. 1979;86:638641.
[52]Light, RJ, Pillemer, DB. Summing up: the science of reviewing research. Cambridge MA: Harvard University Press, 1984.
[53]Egger, M, Davey Smith, G, Schneider, M, Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629634.
[54]Bloomfield, MAP, Hindocha, C, Green, SF, Wall, MB, Lees, R, Petrilli, K, et al.The neuropsychopharmacology of cannabis: a review of human imaging studies. Pharmacol Ther. 2019;195:132161.
[55]Weinstein, A, Livny, A, Weizman, A. Brain imaging studies on the cognitive, pharmacological and neurobiological effects of cannabis in humans: evidence from studies of adult users. Curr Pharm Des. 2016;22:63666379.
[56]Schnakenberg Martin, AM, Bonfils, KA, Davis, BJ, Smith, EA, Schuder, K, Lysaker, PH. Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis. Schizophr Res Cogn. 2016;6:1521.
[57]Giuffrida, A, Leweke, FM, Gerth, CW, Schreiber, D, Koethe, D, Faulhaber, J, et al.Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29:21082114.
[58]Fernandez, E, Galán, B.Neurofisiología de la acción psicotogenética del cannabis y endocannabinoides. In: Arias, F, Ramos, JA, editors. Aspectos psiquiátricos del consumo de cannabis: casos clínicos. Madrid, Spain: Universidad Complutense de Madrid; 2008. p. 926.
[59]Grace, AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 1991;41:124.
[60]Moore, H, West, AR, Grace, AA. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biol Psychiatry. 1999;46:4055.
[61]Hirvonen, J, van Erp, TG, Huttunen, J, Aalto, S, Någren, K, Huttunen, M, et al.Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry. 2005;62:371378.
[62]Rodríguez de Fonseca, F, Del Arco, I, Martín-Calderón, JL, Gorriti, MA, Navarro, M. Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis. 1998;5:483501.
[63]Valenti, O, Grace, AA. Antipsychotic drug-induced increases in ventral tegmental area dopamine neuron population activity via activation of the nucleus accumbens-ventral pallidum pathway. Int J Neuropsychopharmacol. 2010;13:845860.
[64]Kuroki, T, Nagao, N, Nakahara, T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008;172:199212.
[65]Gardner, EL, Vorel, SR. Cannabinoid transmission and reward-related events. Neurobiol Dis. 1998;5:502533.
[66]Pertwee, RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 2005;7:E625E654.
[67]Potter, DJ, Hammond, K, Tuffnell, S, Walker, C, Di Forti, M. Potency of Δ. Drug Test Anal. 2018;10:628635.
[68]Iseger, TA, Bossong, MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015;162:153161.
[69]Schubart, CD, Sommer, IE, Fusar-Poli, P, de Witte, L, Kahn, RS, Boks, MP. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol. 2014;24:5164.
[70]Hahn, B. The potential of cannabidiol treatment for cannabis users with recent-onset psychosis. Schizophr Bull. 2018;44:4653.
[71]Bernardo, M, Bioque, M, Parellada, M, Saiz Ruiz, J, Cuesta, MJ, Llerena, A, et al.Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). Revista Psiquiatria Salud Mental. 2013;6:416.
[72]Moreno-Granados, JM, Ferrín, M, Salcedo-Marín, DM, Ruiz-Veguilla, M. Neuropsychological assessment of memory in child and adolescent first episode psychosis: cannabis and «the paradox effect». Rev Psiquiatr Salud Ment. 2014;7:1324.

Keywords

Type Description Title
WORD
Supplementary materials

Sánchez-Gutiérrez et al. supplementary material
Sánchez-Gutiérrez et al. supplementary material 1

 Word (121 KB)
121 KB
WORD
Supplementary materials

Sánchez-Gutiérrez et al. supplementary material
Sánchez-Gutiérrez et al. supplementary material 2

 Word (14 KB)
14 KB

Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning

  • Teresa Sánchez-Gutiérrez (a1), Belén Fernandez-Castilla (a2), Sara Barbeito (a1), Ana González-Pinto (a3), Juan Antonio Becerra-García (a1) and Ana Calvo (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning

  • Teresa Sánchez-Gutiérrez (a1), Belén Fernandez-Castilla (a2), Sara Barbeito (a1), Ana González-Pinto (a3), Juan Antonio Becerra-García (a1) and Ana Calvo (a1)...
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *